PTGX FDA approves MIMRYLO for erythrocytosis in PV
PTGX says the FDA has approved MIMRYLO for erythrocytosis in PV, described as first-in-class with a broadly labeled therapy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.